Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCYGet Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 36,800 shares, an increase of 1,500.0% from the December 31st total of 2,300 shares. Based on an average daily trading volume, of 214,500 shares, the days-to-cover ratio is currently 0.2 days.

Chugai Pharmaceutical Stock Performance

OTCMKTS:CHGCY opened at $20.63 on Wednesday. The stock has a market capitalization of $67.89 billion, a P/E ratio of 26.45 and a beta of 0.81. The company’s 50-day simple moving average is $21.62 and its 200-day simple moving average is $22.44. Chugai Pharmaceutical has a fifty-two week low of $14.52 and a fifty-two week high of $26.00.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

Featured Stories

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.